Compare AbbVie Inc (ABBV) vs Teucrium Corn Fund (CORN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Teucrium Corn Fund — how do they compare? AbbVie Inc trades at $249.43 (market cap $438.19B), while Teucrium Corn Fund trades at $17.53. The key difference: AbbVie Inc pays a 2.79% dividend while Teucrium Corn Fund pays none, and AbbVie Inc is trading nearer its 52-week high, Teucrium Corn Fund nearer its low. Which is the better fit depends on your goals.
| ABBV | CORN | |
|---|---|---|
Market Cap | $438.19B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $263.58 | $19.12 |
52-Week Low | $197.38 | $16.46 |
Enterprise Value | $502.45B | — |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.19, up 1.28% today, with a bullish technical signal and strong analyst support. Recent earnings beats and robust immunology drug performance from Skyrizi and Rinvoq are offsetting Humira patent losses, driving revenue growth to $61.16B in 2025. The stock is near its pivot point of $247, with support at $245 and resistance at $249.
The outlook remains positive with a consensus price target of $281.33, though high P/E of 70.05 and looming patent cliffs in the 2030s present risks. Dividend growth and institutional accumulation support the buy case, but margin compression and debt levels warrant monitoring.
CORN trades at $17.64, up 0.17% for the day, with technical indicators showing a bearish bias from moving averages despite a neutral oscillator stance and oversold short-term RSI. Recent news highlights strong performance in agricultural ETFs, with CORN returning 9.7% over the past month, driven by inflation trends and geopolitical tensions affecting commodity markets.
The outlook is mixed; positive momentum from commodity strength offers upside, but bearish technicals and reliance on volatile agricultural markets pose risks. Investors should weigh near-term commodity tailwinds against the absence of fundamental financial data and broader market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Teucrium Corn Fund
CORN is a commodity ETF that provides exposure to the price of corn futures. It uses a laddered investment strategy across multiple benchmark contracts to help minimize the impact of contango and roll costs in the agricultural market.
Read more on CORN →
